ACT NOW -
Use VETMEDIN at first clinical signs to keep dogs going
Proven efficacy in clinical trials
VETMEDIN is approved for use as first-line therapy to manage mild, moderate, or severe signs of congestive heart failure (CHF).1 The effectiveness of VETMEDIN in managing dogs with CHF has been thoroughly investigated in FDA-licensing and other clinical studies.1-3 Efficacy trials support the benefits of VETMEDIN in early disease management.2-4
Trial results document the ability of VETMEDIN to improve and lengthen life in dogs with CHF. The QUEST* trial indicated that VETMEDIN virtually doubled survival times.3
In addition, trials showed that VETMEDIN quickly reduced clinical signs—within 1 week.2 Improving quality of life for their dogs is an important factor to pet owners in managing CHF.
Overall, extensive study data indicate that use of VETMEDIN as primary treatment allows dogs with CHF to lead happier, healthier, and longer lives.1-4
Important safety information
VETMEDIN should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons.
The safety of VETMEDIN has not been established in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than atrioventricular valvular insufficiency or dilated cardiomyopathy. Use only in dogs with clinical evidence of heart failure.
The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. If side effects should occur, pet owners should contact their veterinarian.
*Clinical studies were completed using VETMEDIN capsules. In the US, only the chewable tablets are licensed. Both the capsules and chewable tablets contain the same pharmaceutical ingredient, pimobendan, and are considered equivalent for clinical use. Bioequivalence, however, has not been shown.